EGFR and non-small cell lung carcinoma: Among others, the introduction of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) as first-line therapy for the treatment of EGFR-mutated NSCLC patients has led to longer progression-free survival (PFS) and higher response rates compared to platinum-based chemotherapy (3–6).